Document is current
Any future updates will be listed below
-
Authors
Igarashi, Ataru https://orcid.org/0000-0001-6307-6916
Takazono, Takahiro https://orcid.org/0000-0002-0696-5386
Hosogaya, Naoki https://orcid.org/0000-0002-3229-2277
Itsumura, Naoya https://orcid.org/0000-0002-4183-0604
Miyazawa, Shogo https://orcid.org/0009-0003-6314-5872
Fujita, Satoki https://orcid.org/0000-0002-0107-4402
Eymere, Sebastien https://orcid.org/0000-0001-8074-5480
Berdunov, Vladislav https://orcid.org/0000-0002-5743-2184
Dronova, Mariia https://orcid.org/0000-0003-1645-5678
Tytuła, Anna https://orcid.org/0009-0004-8827-1469
Mukae, Hiroshi https://orcid.org/0000-0002-1429-5706
-
Funding
Funding for this research was provided by:
Shionogi
- License Information
-
More Information
Article History
Received: 15 April 2025
Accepted: 17 July 2025
First Online: 27 August 2025
Declarations
:
: Naoya Itsumura, Shogo Miyazawa, and Satoki Fujita are employees of Shionogi & Co., Ltd., who is the manufacturer of baloxavir. Ataru Igarashi, Takahiro Takazono, Naoki Hosogaya, and Hiroshi Mukae have received personal fees from Shionogi & Co., Ltd. Vladislav Berdunov, Sebastien Eymere, Mariia Dronova and Anna Tytuła are or were employees of Putnam, who received funding from Shionogi & Co., Ltd., to conduct this study. At the time of submission of this manuscript, Vladislav Berdunov is an employee of Evidera.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
